Soiken Holdings Inc. is engaged in the development of biomarkers and assessment systems. It operates through the following segments: Evaluation & Testing Biomarker Development, Pharmaceutical Clinical Research Support, Healthcare Support, Cosmetics, Dietary Supplements, and Functional Materials Development. The Evaluation & Testing Biomarker Development segment performs clinical evaluation tests on the function and safety of food. The Healthcare Support segment offers services on health guidance and insurance. The Cosmetics segment produces and sells cosmetics. The Dietary Supplements segment sells health supplements that include imida peptide. The Functional Materials Development segment develops and sells functional materials that include lactoferrin. The company was founded by Osami Kajimoto in July 1994 and is headquartered in Osaka, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company